Slides
Page 1
www.quickheal.com | www.seqrite.comConfidential Please find below the colour palette for this presentation: Select an object / Shape > Go to shape fill > Select eye dropper tool. Pic any colour from the palette. Q2 FY27 October 27, 2026 EARNINGS PRESENTATION
Page 2
Confidential 2 2 GLOBAL CYBERSECURITY TRENDS • Investment & adoption of AI in Cybersecurity • Consolidation of security stack • Privacy driven Application & Data Decoupling • Growing Adoption of Cloud Native Application • Cybersecurity reskilling • Organizations continue to accelerate their multiyear Security Service Edge (SSE) and Zero Trust (ZT) journey • Organizations continue to strengthen their security portfolio with new tools SECRITE I Quick Heal •
Page 3
Confidential 3 3 INDIA CYBER THREAT REPORT: KEY HIGHLIGHTS Primary attack vectors 70% of attacks originated from Trojans and Infectors On-Prem detections contributed 92% while 8% detections were cloud~12 attacks per month per personal end user device Bigger spectrum of detections and endpoints Over 265.52 M detections recorded over8 Million endpoints detections Averaging 505 per minute Behavioral-based detection Increase from 12.5% in 2023 34 million 12.8 % of total detections behavior-based detections, accounted for Source: India Cyber Threat Report 2026 SECRITE I Quick Heal
Page 4
Confidential 4 4 INDIA CYBER THREAT REPORT: KEY HIGHLIGHTS CONTD… Approximately 5 million Cryptojacking detections reported over the year 1 Ransomware incident per 669 detections 1 Malware incident per 42,012 detections Malware and Ransomware incidents Education & Training Healthcare Engineering & Manufacturing 23.8% 18.3% 18.3% Top-most targeted industries Geographical Hotspots 24.3% of detections Maharashtra 16.2% of detections Gujarat 10.4% of detections Delhi NCR 9.7% of detections West Bengal 9.4% of detections Uttar Pradesh Source: India Cyber Threat Report 2026 SECRITE I Quick Heal
Page 5
Confidential 5 5 OUR PURPOSE Innovate Focus on grassroot research and adoption of new tech Simplify Ease of manageability & operations for the end customers Secure Getting the Job Done: Staying one step ahead of the threat actors to protect our customers Innovate to “simplify” securing digital experience SECRITE I Quick Heal 0
Page 6
Confidential 6 6 OUR JOURNEY SO FAR Protected early Generations of PCs 1993-96 Secured PCs, Network & Emails 1996-00 Ensured a safe digital experience for Individuals, Businesses and Government Organizations 2001-05 Threat protection for Smart Phones and Tablets 2006-10 Recognised by NASSCOM’s DSCI as ‘Cyber security Product pioneer in India’ 2017-19 Protecting Data, Transactions & Cloud transitions 2020-23 • CSMA Product Stack • Collaboration with AISIC and NIST- NCCOE • India Cyber Threat Report • Seqrite Brand Refresh • Anti Fraud Launch • International Expansion • Expansion into Privacy & Data Protection 2023-26 SECRITE I Quick Heal
Page 7
Confidential 7 7 THIS IS US Pioneer of cybersecurity in India Presence in 70+ countries 1st Listed Cybersecurity company in India Protecting 9 Million Active Devices ~1000 Cybersecurity Professionals Market Leader in India Patents Protecting Critical Infrastructure of India Collaborators with US bodies NIST & AISIC Proud Owners of Seqrite Labs: Largest in the country ••• --- - e SECRITE I Quick Heal
Page 8
Confidential 8 8 FOUNDED BY THE VISIONARIES Dr. Kailash Katkar Chairman and Managing Director Dr. Sanjay Katkar Joint Managing Director A Visionary Founder and Leader, a Born Entrepreneur, and an Exemplary Trailblazer, he has transformed Quick Heal into a beacon of success and innovation in the Cybersecurity industry. His business acumen has consistently driven Remarkable financial performance, customer satisfaction, market leadership making Quick Heal & SEQRITE the preferred choice for customers globally. Dr. Sanjay Katkar: Co- Founder of Quick Heal Technologies Limited, Joint Force, and Technology Powerhouse behind the company's journey. An unmatched Cybertech Mastermind, who is relentlessly shaping the company’s global technology strategy and driving core research and development while pursuing product innovation to fortify cyber security. SECRITE I Quick Heal Dr. Kailash Katkar Dr. San jay Katkar
Page 9
Confidential 9 9 LED BY THE INDUSTRY EXPERTS Harish Kumar Chief Executive Officer Ankit Maheshwari Chief Financial Officer Anupama Katkar COE at QH & Chairperson QHF Rajiv Sreekantan Senior Vice President Enterprise Sales Netra Deshpande Head of Engineering Sangamesh S Head of Seqrite Labs Amit Chaudhary Vice President – Product Management Deepak Mishra Head, Retail Sales Nitin Bhogan Head of Academy Ashish Kadam Director, Government Sales Amartya Mukherjee Vice president & Head of Delivery Savita Nehra Vice President, People & Culture Rohit Kachroo Sr Director, IT & Digital Transformation An industry veteran with over three decades of experience in the technology sector, Harish has a proven track record of driving growth, scaling up iconic brands, and building high-performance teams. He is focused on strengthening Quick Heal's position as a trusted cybersecurity leader through innovation, customer-centricity, and operational excellence. SECRITE I Quick Heal Ankit Anupama Rajiv Netra SangameshS Amit Maheshwari Katkar Sreekantan Deshpande Chaudhary Harish Kumar Chief Financial COE at OH & Senior Vice President Head of Head of Seqrite Vice President - Chief Executive Officer Officer Chairperson QHF Enterprise Sales Engineering Labs Product Management Rohit Deepak Amartya Savita Nitin Ashish Kachroo Mishra Mukherjee Nehra Bhogan Kadam Sr Director, IT & Digital Head, Vice president & Vice President, Head of Director, Transformation Retail Sales Head of Delivery People & Culture Academy Government Sales
Page 10
Confidential 10 10 OUR STRATEGY & WAY FORWARD SECRITE I Quick Heal
Page 11
Confidential 11 11 EXPANDING ACROSS 3 LEVERS Product Stack Holistic cybersecurity stack for better protection and increased wallet share Large Customers Moving up the customer segments as the solutions mature Niche Solutions specifically targeted to Large Enterprises (SDP) and Mid Enterprises (Threat Management) Geographic Reach Setting up a strong foot in Indian Market Strategic Expansion in select focused geographies SECRITE I Quick Heal
Page 12
Confidential 12 12 SEQRITE SOLUTION STACK An approach to simplify cybersecurity by integrating security tools across a distributed enterprise SECRITE I Quick Heal
Page 13
Confidential 13 13 OUR RIGHT TO WIN • Solving unique value propositions & use cases (E.g.: On prem & cloud) • Best in class support offerings • Largest Cybersecurity Lab in India with unique telemetry • Simple Integrated Architecture • Adoption of the new age tech in our stack • Holistic platformised cybersecurity solution • Strong Partner Network across the country • Make in India • Proximity to the customers in India SECRITE I Quick Heal
Page 14
Confidential 14 14 AWARDS & RECOGNITIONS Quick Heal is certified as one of the safest for browsing & banking by AVLab, Poland Quick Heal is certified the “Product of the year” by AVLab, Poland Seqrite Endpoint Protection for Best Performance by AV-Test Seqrite Endpoint Protection Achieves AV- TEST Approved – Top Product - Corporate Endpoint Protection SECRITE I Quick Heal
Page 15
Confidential 15 Q2 FY27 BUSINESS HIGHLIGHTS
Page 16
Confidential 16 16 BUSINESS HIGHLIGHTS • Key strategic account wins in Defense, BFSI & large IT services company through our new gen products in H1 • Strong momentum in the government vertical • Order Book: INR 57 Cr+ • Deferred Revenue: INR 48.3 Cr (Q1FY27: 52.3 Cr) • Tighter credit controls in the Consumer business • Onboarding of Key Leadership across Sales & Product functions SECRITE I Quick Heal
Page 17
Confidential 17 17 Q2 FY27: PERFORMANCE HIGHLIGHTS *Based on gross revenues excluding deferred revenue, before adjusting for sales incentives ₹ 64.9 Cr Net Revenue -22.3% YoY 44.3% QoQ ₹ 2.3 Cr EBITDA -75.2% YoY 113.0% QoQ ₹ 5.8 Cr PAT -26.8% YoY 209.7% QoQ ₹ 1.0 Diluted EPS -27.4% YoY 209.2% QoQ ₹ 35.5 Cr * Enterprise Revenue -3.9% YoY 18.1% QoQ ₹ 35.8 Cr * Consumer Revenue -39.8% YoY 86.2% QoQ SECRITE I Quick Heal
Page 18
Confidential 18 18 DECONSTRUCTING CURRENT BUSINESS ConsumerEnterprise 46% 54% FY 2021 H1 FY 2027FY 2026 49%51% 80% 20% SECRITE I Quick Heal ■ ■
Page 19
Confidential 19 19 ENTERPRISE BUSINESS CLOUD & ON-PREM 38% 62% 31% 69% FY 2025 FY 2026 H1 FY2027 Cloud On-Prem 31% 69% SECRITE I Quick Heal ■ ■
Page 20
Confidential 20 20 KEY FINANCIAL HIGHLIGHTS Gross Revenue Consumer Gross Revenue Enterprise Total Deferred Revenue All figures in INR Cr Total Receivables 37 30 36 Q2FY26 Q1FY27 Q2FY27 +18% 60 19 36 Q2FY26 Q1FY27 Q2FY27 +86% 18 52 48 Q2FY26 Q1FY27 Q2FY27 -8% 176 107 98 Q2FY26 Q1FY27 Q2FY27 -8% SECRITE I Quick Heal
Page 21
Confidential 21 21 SEQRITE: ENTERPRISE ARM OF QUICK HEAL FY16 FY23-24 FY25FY17 – 22 FY26-27 • Investments in EDR, XDR, Zero Trust & Data Privacy products • Crossed 100 Cr in revenue • Mid-Market Capture SMB Market Capture & Leadership Foray into Enterprise Segment with Seqrite Endpoint Protection • Horizon-3 Product • Material New Product Revenue • Projects & Order Book • SIA Launch • Government segment penetration • International Expansion • Data Privacy Market Entry • DRPS and RRaaS launched SECRITE I Quick Heal
Page 22
23rd Elets NBFC100 Tech Summit, Chennai | 9 July 2026 Seqrite + JISA Webinar: Implementing DPDP the Right Way | 23 July 2026 Kerala Cyber Suraksha Summit (KCSS) 2026, Kochi | 5 September 2026 15th GISEC Global 2026, Dubai | 16-18 September 2026 ENTERPRISE MARKETING CAMPAIGNS SECRITE I Quick Heal
Page 23
Confidential 23 23 MARKET LEADER: CONSUMER ANTIVIRUS BUSINESS Positioning AntiFraud.AI to tackle the financial frauds Focus towards maintaining our market share in AV segment Drive consumer awareness in the geography in cybersecurity specific domain 30 years into existence Market leadership with over 30% in the Indian market Robust Sales & Distribution network in India Our Approach: SECRITE I Quick Heal • • 0 QUICK HEAL QUICK HEAL ' • INTERNET SECURITY TOTAL SECURITY QUICK HEAL ANTIVIRUS PRO • C ;; 0 . ~ ~ • ; z • ~ ~ i ~ • -4) -, ,.,. ,..,,,,_ ,.,.,_ I~ "" -.,p11111K! •
Page 24
Confidential 24 24 CONSUMER MARKETING CAMPAIGNS Festive activities Student Campaign Partner Communications Booster for Sales - T3 partner COMPLETE YOUR ACT IVATIONS . Exer11g1vE REWARD How to Earn Your Reward !ll01 !ll02 !ll03 !ll04 Purchase Activate Enaurelhe Receive ■ QuickHoat 50% lirstacanis Porta ble products dooethrO!Jlh &tender& worth (~22,000) the RPP Pot"Ut Julc:erworth ~44.000 durlngthe ~4.999 scheme period Importan t Deta ils $(;heme PwiOd: 1 -31 Ck:tober 2026 I °'PP!H;8bl ■ tor Rqi sterlld T3 Panner1 Eli&ibtlity based on the llrst scan ,n the RPP Portal I o,tts will be d1spatc;hecl to the reaisterad partner address I •ontyooe aitt will De awarded per eUIJbte dealer. For mor•d•U11l1 callYoVrArea Sales Manager oeeo i'!uld<hNI Here's to every first click that brings celebration clos SECRITE I ~ SECRITE l l:m:m ■ 'l'lioln.Aoo;,-~ Contro l and restrict You Tube access across all business device s. ..... . 0 SECRITE I Quick Heal
Page 25
Confidential 25 25 CSR UPDATE Maharashtra, Karnataka, Gujarat, West Bengal, Chhattisgarh, Uttar Pradesh, Assam, Punjab, Jammu & Kashmir, Madhya Pradesh, Kerala , Goa, Odisha, Haryana, Tamil Nadu, Rajasthan, Bihar, Jharkhand, Puducherry Total Outreach 1 Cr+ Cyber Shiksha for Cyber Suraksha Total States Covered 19 SECRITE I Quick Heal
Page 26
Confidential 26 Q2 FY27 FINANCIAL HIGHLIGHTS
Page 27
Confidential 27 27 CONSOLIDATED P&L All figures in INR Cr PARTICULARS Q2 FY26 Q1 FY27 Q2 FY27 Revenue 83.5 45.0 64.9 Direct Cost 2.6 0.8 4.3 Gross Profit 81.0 44.2 60.7 Gross Margin 96.9% 98.2% 93.5% Operating Cost Research and Development 32.9 28.1 27.1 Sales and Marketing 22.5 20.9 19.1 General Administration 16.3 12.8 12.2 Total Expenditure 71.7 61.8 58.4 EBITDA 9.2 (17.6) 2.3 EBITDA % 11.1% -39.1% 3.5% Depreciation 3.3 3.9 5.8 EBIT 6.0 (21.4) (3.5) Other Income 4.4 14.1 8.3 Finance Cost (0.1) 0.0 (0.5) Profit Before Tax (PBT) 10.3 (7.3) 4.3 Tax 2.4 (2.0) (1.5) Profit After Tax (PAT) 7.9 (5.3) 5.8 PAT Margin 9.5% -11.7% 8.9% H1 FY26 H1 FY27 140.8 109.9 3.5 5.0 137.3 104.9 97.5% 95.4% 64.2 55.2 43.6 40.0 30.0 25.0 137.8 120.2 (0.5) (15.3) -0.4% -13.9% 6.2 9.6 (6.7) (24.9) 10.1 22.4 (0.1) (0.5) 3.3 (3.0) 0.9 (3.5) 2.4 0.5 1.7% 0.5% SECRITE I Quick Heal
Page 28
Confidential 28 28 BALANCE SHEET All figures in INR Cr ASSETS Mar 31, 2026 Sep 30, 2026 Non-Current Assets: Property, plant and equipment 87.6 62.7 Capital work-in-progress 0.0 1.3 Intangible assets 1.3 1.0 Investment Property 32.2 54.0 Right-of-use assets 1.1 31.6 Non-current financial assets Investments in MF, Tax-Free Bonds & others 7.5 7.8 Other Financial Asset 0.8 3.2 Deferred tax assets (net) 17.5 19.7 Income tax assets (net) 25.0 11.0 Other Non Current assets 5.3 2.2 Total Non-Current Assets 178.3 194.3 Current assets: Inventories 2.6 1.8 Investments 205.2 256.3 Trade and other receivables 137.6 97.8 Cash and Cash Equivalents 13.1 5.3 Bank Balance other than cash & cash equivalents 0.1 0.1 Other Financial Assets 1.1 1.7 Other Current assets 9.0 11.9 Total Current Assets 368.7 374.8 Total Assets 547.0 569.1 EQUITY AND LIABILITIES Mar 31, 2026 Sep 30, 2026 Equity Equity Share Capital 54.2 54.3 Other Equity 382.3 381.9 Total Shareholder Funds 436.5 436.2 Non-Current Liabilities Lease Liabilities - 24.4 Employee benefit obligations 2.0 2.0 Other Non Current Liabilities 0.2 8.7 Total Non-Current Liabilities 2.2 35.0 Current Liabilities: Trade and Other Payables 41.1 29.4 Other Financial Liabilities 4.5 7.6 Contract Liabilities 33.8 39.9 Other Current Liabilities 8.4 6.7 Employee benefit obligations 20.5 14.3 Total Current Liabilities 108.3 97.9 Total Equity & Liabilities 547.0 569.1 SECRITE I Quick Heal
Page 29
Confidential 29 29 CASH FLOW STATEMENT All figures in INR Cr PARTICULARS Sep 30, 2025 Mar 31, 2026 Sep 30, 2026 Net cash flow from / (used in) operating activities (A) (5.4) 15.4 39.6 Net cash flow from / (used in) investing activities (B) (10.3) (25.7) (44.8) Net cash flow from / (used in) financing activities (C) 1.6 2.8 (2.6) Net (decrease) in cash and cash equivalents (A+B+C) (14.1) (7.6) (7.9) Cash and cash equivalents at the beginning of the period 20.8 20.8 13.1 Effect of exchange differences on cash and cash equivalents held in foreign currency (0.0) (0.1) - Cash and cash equivalents at the end of the period 6.7 13.1 5.3 Components of cash and cash equivalents Cash in hand 0.0 0.0 0.0 Balances with banks and cheques on hand 6.7 13.1 5.3 Total cash and cash equivalents 6.7 13.1 5.3 SECRITE I Quick Heal
Page 30
Confidential Stock Market Performance (as on 30th September2026) Price Data (as of 30th September 2026) Face Value 10.00 Market Price 144.85 52 Week H/L 371.00/125.00 Market Cap (INR Mn) 7,863.51 Equity Shares Outstanding (Mn) 54.27 1 Year Avg. Trading Volume ('000) 593.14 1 Year Avg. Net Turnover (Mn) 135.62 -80% -60% -40% -20% 0% 20% 40% Oct-25 Nov-25 Dec-25 Jan-26 Feb-26 Mar-26 Apr-26 May-26 Jun-26 Jul-26 Aug-26 Sep-26 Sensex Quick Heal-BSE Promoter, 71% Other, 5% Public, 24% Shareholding Pattern (as on 30th September 2026) CAPITAL MARKET DATA
Page 31
Confidential 31 31 DISCLAIMER Quick Heal Technologies Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness, or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward-looking statements" based on the currently held beliefs and assumptions of the management of Quick Heal Technologies Limited, which are expressed in good faith and in their opinion reasonable, including those relating to the Company’s general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment. Forward-looking statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company or industry results to differ materially from the results, financial condition, performance, or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company’s business, its competitive environment, and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties, and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments. This presentation is for general information purposes only, without regard to any specific objectives, financial situations, or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration therefrom. This presentation is confidential and may not be copied or disseminated, in whole or in part, and any manner. Valorem Advisors Disclaimer: Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness, and reasonableness of the contents of this Presentation. This Presentation may not be all-inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review. SECRITE I Quick Heal
Page 32
www.quickheal.com | www.seqrite.comConfidential Please find below the colour palette for this presentation: Select an object / Shape > Go to shape fill > Select eye dropper tool. Pic any colour from the palette. THANK YOU